Hauro Hirayama, MD, PhD

Review

Management of Drug-Eluting Stent Restenosis

03/27/2012

Abstract: In-stent restenosis has been a longstanding problem after percutaneous coronary intervention. The introduction of the drug-eluting stent (DES) successfully reduced the rate of restenosis; however, it is not completely diminished....

Abstract: In-stent restenosis...

03/27/2012

Journal of Invasive Cardiology

Original Contribution

Mid-Term Results of Everolimus-Eluting Stent in a Japanese Population Compared With a US Randomized Cohort: SPIRIT III Japan Registry With Harmonization by Doing

08/29/2012

Alexandra J. Lansky , MD;

Krishnankutty Sudhir , MD, PhD;

Takaaki Isshiki , MD;

Tadashi Kikuchi , MD, PhD;

Hiroshi Nonogi , MD, PhD;

Keiichi Igarashi , MD;

Kenshi Fujii , MD;

Kumiko Saito , MS, MPH;

Hiroshi Fujita , MD;

Shigeru Nakamura , MD;

Shigeru Saito , MD;

Kazuaki Mitsudo , MD;

Masato Nakamura , MD;

Takeshi Kimura , MD;

Hauro Hirayama , MD, PhD;

Gregg W. Stone , MD, FACC, FSCAI;

Yasuhiro Honda , MD;

Peter J. Fitzgerald , MD, PhD;

Katsuhisa Waseda , MD, PhD;

Abstract: To address safety concerns with first-generation drug-eluting stents (DESs), the everolimus-eluting stent (EES) has been developed as a second-generation DES. The study aim was to: (1) demonstrate that use of the EES in Japanese...

Abstract: To address safety...

08/29/2012

Journal of Invasive Cardiology